TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04209504

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound guided evaluation of diaphragm ipsilateral to the block side.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound guided evaluation of diaphragm ipsilateral to the block side.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound guided evaluation of diaphragm ipsilateral to the block side.

Intervention type: DRUG
Intervention: Ropivacaine
Description: Local anesthetic (numbing drug)

Intervention type: DRUG
Intervention: Bupivacaine
Description: Local anesthetic (numbing drug)

Intervention type: DRUG
Intervention: Bupivacaine
Description: Local anesthetic (numbing drug)

Intervention type: DEVICE
Intervention: MediPines AGM100 Advanced Respiratory Monitoring System
Description: Non-invasive respiratory monitor to measure oxygenation and ventilation parameters

Intervention type: DEVICE
Intervention: MediPines AGM100 Advanced Respiratory Monitoring System
Description: Non-invasive respiratory monitor to measure oxygenation and ventilation parameters

Intervention type: DEVICE
Intervention: MediPines AGM100 Advanced Respiratory Monitoring System
Description: Non-invasive respiratory monitor to measure oxygenation and ventilation parameters
Study: NCT04093323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-type-1 Polarized Dendritic Cells
Description: Given ID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Ligand Inhibitor
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1 Inhibitor
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: Given IV
Study: NCT04612049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality visuo-motor skill assessment
Description: Visuo-motor skill assessment in an immersive 3D virtual environment using a head-mounted display.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality visuo-motor skill assessment
Description: Visuo-motor skill assessment in an immersive 3D virtual environment using a head-mounted display.
Study: NCT06441227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5346 tablets
Description: Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.
Study: NCT05958433

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation with stoma appliance
Description: The rehabilitation group will receive preoperative stoma education in addition, a water-filled ostomy appliance (50-100 ml) will be attached 48 hours before surgery. These pouches will not be removed until surgery, and the EST nurse will teach the patients preoperatively how to manage the ostomy appliance with similar standards as described in the usual postoperative stoma care.
Study: NCT06441227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5346 tablets
Description: Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5346 tablets
Description: Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.
Study: NCT06304311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine Obstetrics care & Lamaze breathing techniques and backside massage
Description: Lamaze breathing techniques Five breathing patterns were introduced namely- cleansing breathing for relaxation, slow-paced breathing, modified-paced breathing and patterned- paced breathing. These patterns were used during and following contractions. Gentle pushing, and breath-hold during pushing were instructed during the second stage of labor which encouraged descent of the baby.~Backside massage during 2nd stage of labor by the trained massage therapist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine Obstetrics care & Lamaze breathing techniques and backside massage
Description: Lamaze breathing techniques Five breathing patterns were introduced namely- cleansing breathing for relaxation, slow-paced breathing, modified-paced breathing and patterned- paced breathing. These patterns were used during and following contractions. Gentle pushing, and breath-hold during pushing were instructed during the second stage of labor which encouraged descent of the baby.~Backside massage during 2nd stage of labor by the trained massage therapist.
Study: NCT04679883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% GLH8NDE
Description: 5% GLH8NDE as eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% GLH8NDE
Description: 5% GLH8NDE as eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo as eye drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as eye drops
Study: NCT05552690

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood draw
Description: 10 ml of blood will be draw to genetic analysis (sequencing)
Study: NCT04962893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 VLP Vaccine-Wuhan
Description: Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 VLP Vaccine-Alpha (British) variant
Description: Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant
Description: Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the Wuhan or Alpha variants
Study: NCT06234137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 iv escalating to 100mg/m2 iv 3-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=6 min/mL iv 3-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inetetamab
Description: 8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400mg orally daily
Study: NCT06570681

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Video call assisted assessment of acute stroke
Description: If the patient is eligible for study inclusion, eight symptoms from the study protocol are evaluated and registered in the Prehospital Patient Journal (PPJ) on the amPHITM Prehospital Health Care Record (Amphi Systems, Hasserisvej 125, 9000 Aalborg, Denmark), on a tablet mounted in each EMT vehicle. Afterwards, the EMS personnel will contact the on-call neurologist and if the vehicle is in the intervention arm a live video stream is initiated. The on-call neurologist then examines the patient via via the video-call and triages the patient.
Study: NCT06372041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Alternating Current Stimulation
Description: tACS will be performed by using a Conformite Europeenne (CE) marked stimulator device (Starstim ®, Neuroelectrics, Barcelona, Spain). By applying alternating current at the gamma frequency band (range 30-80), known to be associated to motor performance, tACS can entrain or synchronize neural oscillations in the targeted brain regions. By modulating cortical excitability of the cerebellum, a region strongly involved in motor learning and coordination, tACS is expected to influence the strength and coordination of motor responses elicited during the training. tACS will be delivered through two saline-soaked surface sponge electrodes (dimension: 25cm2 each), one placed over F3 (left frontal region) and the other over the right cerebellar hemisphere. The intensity will be set to 1mA, and this value will be gradually reached with a ramping-up phase of 30 secs. The frequency of the stimulation will match the IGF identified during the EEG recording performed at rest.
Study: NCT05539391

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data patient
Description: Medical History and characteristic of patient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data patient
Description: Medical History and characteristic of patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical examination
Description: Arterial pressure, arterial oxygen saturation, heart rate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical examination
Description: Arterial pressure, arterial oxygen saturation, heart rate
Study: NCT06372041

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Alternating Current Stimulation
Description: tACS will be performed by using a Conformite Europeenne (CE) marked stimulator device (Starstim ®, Neuroelectrics, Barcelona, Spain). By applying alternating current at the gamma frequency band (range 30-80), known to be associated to motor performance, tACS can entrain or synchronize neural oscillations in the targeted brain regions. By modulating cortical excitability of the cerebellum, a region strongly involved in motor learning and coordination, tACS is expected to influence the strength and coordination of motor responses elicited during the training. tACS will be delivered through two saline-soaked surface sponge electrodes (dimension: 25cm2 each), one placed over F3 (left frontal region) and the other over the right cerebellar hemisphere. The intensity will be set to 1mA, and this value will be gradually reached with a ramping-up phase of 30 secs. The frequency of the stimulation will match the IGF identified during the EEG recording performed at rest.
Study: NCT06636331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Suprainguinal Fascia Iliaca Compartment Block
Description: Using PCRA and Local Anesthetic Ropivacaine 0.2% continuous 2ml/hr and demand dose 5ml as needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Epidural
Description: Using PCEA and Local Anesthetic Ropivacaine 0.2% continuous 2ml/hr and demand dose 5ml as needed.
Study: NCT04732221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5475
Description: MK-5475 (soluble guanylate cyclase stimulator) 380 µg, 100 µg or 32 µg administered as dry powder inhalation
Study: NCT05539391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid sequence intubation (RSI) : Rocuronium /Bag-mask ventilation /GEB
Description: Rapid sequence intubation (RSI) will be performed with use of rocuronium as paralytic agent (1.2 mg/ kg). Bag-mask ventilation between induction and laryngoscopy will be performed. The GEB will be systematically used at the first attempt to facilitate intubation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid sequence intubation (RSI) : Recommendations for emergency intubation
Description: Rapid sequence intubation (RSI) using succinylcholine as a paralytic agent (1 mg/kg), no systematic bag-mask ventilation between induction and laryngoscopy, use of GEB to facilitate intubation in case of intubation failure under direct laryngoscopy.
Study: NCT06486441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan-hziy
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously
Study: NCT04732221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5475
Description: MK-5475 (soluble guanylate cyclase stimulator) 380 µg, 100 µg or 32 µg administered as dry powder inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5475
Description: MK-5475 (soluble guanylate cyclase stimulator) 380 µg, 100 µg or 32 µg administered as dry powder inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5475
Description: MK-5475 (soluble guanylate cyclase stimulator) 380 µg, 100 µg or 32 µg administered as dry powder inhalation
Study: NCT05602597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Description: Study participants will be administered 200 mg itraconazole by mouth twice daily after the pharmacokinetic blood draw on Day 3 and once daily on Days 4 to 10, inclusive.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg
Description: Study participants will be administered 400 mg fluconazole by mouth daily on Day 3 after the pharmacokinetic blood draw, and 200 mg fluconazole by mouth daily on Days 4 to 10, inclusive.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg
Description: Study participants will be administered 600 mg rifampin by mouth daily starting on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 11, inclusive.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg
Description: Study participants will be administered 40 mg rabeprazole by mouth daily on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 9, inclusive.
Study: NCT04732221

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK-5475
Description: Placebo administered as dry powder inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK-5475
Description: Placebo administered as dry powder inhalation
Study: NCT06047873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: clinical and endoscopic pattern in patients with upper and lower gastrointestinal bleeding
Study: NCT06024005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Solifenacin 5mg
Description: Oral solifenacin (Kinzy 5mg) use once a day for 6 weeks
Study: NCT04855747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: REL-1017 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT06024005

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Posterior Tibial Nerve Stimulation (TTNS)
Description: Application of TTNS twice a week for 6 weeks, with each session for 30 minutes
Study: NCT04770272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 840 MG in 14 ML Injection
Description: 840 mg Day 1 for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 MG in 20 ML Injection
Description: 1200 mg Day 1 every 3 weeks for 8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab 1200 MG in 20 ML Injection
Description: 1200 mg Day 1 every 3 weeks for 8 cycles
Study: NCT06514261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study: NCT04770272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dosing according to Area Under the Curve of 2 Intravenous weekly x 12 cycles
Study: NCT06514261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buccal Swab
Description: Undergo buccal swab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iadademstat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06085807

Intervention type: OTHER
Intervention: Survey
Description: Groups will receive a survey to assess attitudes about diagnosis, treatment, and genetic testing in ADPKD.

Intervention type: OTHER
Intervention: Survey
Description: Groups will receive a survey to assess attitudes about diagnosis, treatment, and genetic testing in ADPKD.
Study: NCT05586763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg)
Description: Each patient with vertigo symptoms will be registered in vertigo list after written consent taken. The ED doctor will take one paper from the vertigo list box and will write the case there including patient ID, date, age and symptoms. Assessment (VAS \& EEV) will be done in the pre- medication 0 min, and at 60 mins posts anti-vertigo medication. The medication will be provided blindly through the pharmacy. Any possible medication side effect and any possible further work up done for patient will be involved in each paper as ED doctor will put a tick near each point. Score will be written in papers as per patient evaluation of their symptoms grade from 1-10. The need for rescue medication ( betahisten or ondansetron ) will be recorded in the paper or is need eply manuver. Principle investigator in each centre will be responsible to collect the papers for analysis by end of each weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg)
Description: Each patient with vertigo symptoms will be registered in vertigo list after written consent taken. The ED doctor will take one paper from the vertigo list box and will write the case there including patient ID, date, age and symptoms. Assessment (VAS \& EEV) will be done in the pre- medication 0 min, and at 60 mins posts anti-vertigo medication. The medication will be provided blindly through the pharmacy. Any possible medication side effect and any possible further work up done for patient will be involved in each paper as ED doctor will put a tick near each point. Score will be written in papers as per patient evaluation of their symptoms grade from 1-10. The need for rescue medication ( betahisten or ondansetron ) will be recorded in the paper or is need eply manuver. Principle investigator in each centre will be responsible to collect the papers for analysis by end of each weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg)
Description: Each patient with vertigo symptoms will be registered in vertigo list after written consent taken. The ED doctor will take one paper from the vertigo list box and will write the case there including patient ID, date, age and symptoms. Assessment (VAS \& EEV) will be done in the pre- medication 0 min, and at 60 mins posts anti-vertigo medication. The medication will be provided blindly through the pharmacy. Any possible medication side effect and any possible further work up done for patient will be involved in each paper as ED doctor will put a tick near each point. Score will be written in papers as per patient evaluation of their symptoms grade from 1-10. The need for rescue medication ( betahisten or ondansetron ) will be recorded in the paper or is need eply manuver. Principle investigator in each centre will be responsible to collect the papers for analysis by end of each weeks.
Study: NCT05773898

Intervention type: OTHER
Intervention: other
Description: The interviewers will collect data from relatives using questionnaires and evaluation grids based on an identification form, a Life Trajectory questionnaire, an anthropological evaluation grid, a retrospective psychiatric diagnosis questionnaire (SCID), a socio-demographic questionnaire, a questionnaire on suicide risks and a questionnaire on emotional state.
Study: NCT05380739

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Working Memory Training
Description: A 10-session working memory (WM) training program
Study: NCT04770272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Dosing according to Area Under the Curve of 2 Intravenous weekly x 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m² IV weekly x 12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m² IV weekly x 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m2, day 1 for 4 cycles (12 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 90 mg/m2, day 1 for 4 cycles (12 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, day 1 for 4 cycles (12 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2, day 1 for 4 cycles (12 weeks)
Study: NCT05380739

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Working Memory Training
Description: A 10-session working memory (WM) training program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Working Memory Training
Description: A 10-session working memory (WM) training program
Study: NCT06638307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN2312
Description: MEN2312 administered as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN2312
Description: MEN2312 administered as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Elacestrant administered as oral tablets.
Study: NCT04675710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO